Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-21 (canceled)

22 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of ~~claim 1 to the animal~~the formula (I):



(I)

wherein: X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

Z is –S-, -SO-, or-SO_2-;

R_1 is selected from the group consisting of:

-alkyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkenyl;

-R_4–aryl;

-R_4– heteroaryl;

-R_4–heterocyclyl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

- alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-CO-O-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently H or C_{1-10} alkyl;

R_4 is alkyl or alkenyl;

Y is –O– or –$S(O)_{0-2}$-;

n is 0 to 4; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

23-25 (canceled)

26 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound ~~of claim 12 to the animal~~selected from the group consisting of:

2-butyl-1-[4-(phenylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[4-(phenylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[4-(methylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[4-(methylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(phenylthio)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[4-(phenylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[4-(methylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[4-(phenylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[4-(methylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-methyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-ethyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-hexyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[5-(methylthio)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[5-(methylsulfinyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[3-(methylsulfonyl)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine; and

2-butyl-1-[3-(phenylsulfonyl)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

27-30 (canceled)

31 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of ~~claim 13 to the animal~~the formula (II):



(II)

wherein: X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

Z is –S-, -SO-, or $-SO_2-$;

R_1 is selected from the group consisting of:

-alkyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkenyl;

$-R_4$–aryl;

$-R_4$– heteroaryl; and

$-R_4$–heterocyclyl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

- alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-CO-O-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently H or C_{1-10} alkyl;

R_4 is alkyl or alkenyl;

Y is –O– or –$S(O)_{0-2}$-;

n is 0 to 4; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

32 (new) The compound 2-butyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine or a pharmaceutically acceptable salt thereof.

33 (new) A method of inducing cytokine biosynthesis in an animal comprising administering a compound of claim 32 to the animal in an amount effective for cytokine induction.

34 (new) A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of claim 32 that induces cytokine biosynthesis.

35 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of claim 32 that induces cytokine biosynthesis.